AdvaMed locks horns with CMS over long-awaited ACO ruling
This article was originally published in Clinica
AdvaMed has voiced its concerns on the final ruling of the Accountable Care Organization (ACO) regulation issued by the US Centers for Medicare and Medicaid Services (CMS) last week, arguing that it stifles healthcare innovation.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.